Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
India's thriving biotechnology industry is threatened by a change in the law. Will the current high levels of investment be enough to secure its future? K. S. Jayaraman finds out.
One of the largest ever vaccine studies is under way in Kolkata. Paroma Basu uncovers the benefits, and difficulties, of inoculating 60,000 people against cholera and typhoid fever.
Drug companies are converging on India to conduct low-cost clinical trials. But is it ready to become the outsourcing centre for the world? T. V. Padma investigates.
India's life-sciences institutes are rewriting the rule books for research. K. S. Jayaraman finds that they are focusing on higher standards and enterprise.
